

**INTRODUCTION TO LLS
THERAPY
ACCELERATION
PROGRAM**

October 2019

BLOOD CANCERS

Every 3 minutes someone in the US is diagnosed with a blood cancer.

More than one third of blood cancer patients do not survive five years after diagnosis.

Despite improved outcomes, we need to do more!

OUR MISSION

Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families



**More than \$1.3 billion
invested in research**




**Unparalleled patient
support and education
services**




**Advocacy to accelerate
cures and access**

LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients




Research by Funding Mechanism - FY18



Therapy Acceleration Program (TAP) PAGE 6


- Strategic initiative established in 2007
- Accelerate high-risk innovative blood cancer therapeutics
- **Meeting LLS Mission is first priority**
- Generating ROI to further fund LLS Mission is secondary



Therapy Acceleration Program (TAP) Supports Emerging New Therapies

- **Venture Philanthropy since 2007**
- **\$120M+ investment**
- **60+ projects**
- **18 in current portfolio**

- **3 FDA Approvals**
 - **Vyxeos (AML)**
 - **Yescarta (DLBCL, tFL, PMBCL)**
 - **Elzonris (BPDCN)**













Development Stages of TAP Portfolio

	Current	Total
<i>Development Phase</i>		
Phase II Reg / Phase III	3	7
Phase II (Non Registration)	7	11
Phase I	5	23
Preclinical	2	19
Clinical Trial Networks/ Patient Care	1	4
TOTAL	18	64

Current Focus:
Clinical Proof of Concept

Select Projects in Current TAP Portfolio PAGE 9

THERAPY	TARGET/MODALITY	INDICATION(S)	PHASE I	PHASE II	PHASE II REG/ PHASE III
ATIR101 (haplo-transplant)	Cell Therapy	AML & ALL			
Cobomarsen	mIR-155 Small Molecule	Cutaneous T-cell Lymphoma			
Hu5F9-G4 + Azacitidine	Anti-CD47 Antibody	MDS			
Hu5F9-G4 + Rituximab	Anti-CD47 Antibody	Lymphoma			
COPIKTRA (duvelisib)	PI3K δ/γ Small Molecule	Peripheral T-cell Lymphoma			
X4P-001 + Ibrutinib	CXCR4 Small Molecule	Waldenstrom Macroglobulinemia			
STRO-001	Anti-CD74 Antibody Drug Conjugate	Lymphoma Myeloma			
SEL120	CDK8/19 Small Molecule	AML			
NK cells + ALT-803	Cell Therapy	Heme Malignancies			
JNJ-40346527	CSF-1R Small Molecule	AML			


LLS TAP Process



- Open to funding application year round
- All hematological indications
- Focuses on therapeutics development in the clinic
- Typically \$2-6M dollars (co-funding for companies)
 - equity or milestone based
- Applicants fill out 1-page Inquiry Form to start the process

How to apply for TAP: www.lls.org/therapy-acceleration-program

LLS TAP Funding Is Competitive



Average annual number; typically 3-6 month to reach TAP Committee Review

- **Subcommittee of LLS National Board**
- Members consist of KOLs, IP lawyer, VC-investors in biotech, Industry veterans
- TAP Research performs S&E and recommends TAP projects to the Committee
- Company presents to the TAP Committee
- The Committee may approve, conditionally approve or reject company funding request
- Committee approval provides Research BD to proceed to Term Sheet and then formal Agreement


Key Criteria

- **High Unmet Medical Need**
- Innovative Science
- First-in-Class
- High potential to impact clinical practice
- Clinical PoC Study or Registration-Directed Study
- Strong IP Position
- Competent Management Team
- Solid Corporate Finance

Why Companies Come to TAP in addition to \$\$

- Deep knowledge of blood cancer landscape
- Expertise in hem/onc clinical development within LLS and via KOLs
- Connections to patients
- Advocacy efforts for patients
- Biotech companies leverage LLS approval to raise additional funds
- Track record of success

TAP is Bridging the Gap for Biotech



BEATING CANCER IS IN OUR BLOOD.





THANK YOU

We have one goal: A world without blood cancers

